Literature DB >> 2810294

The role of cytokines in chondrocyte mediated cartilage degradation.

M Shinmei1, K Masuda, T Kikuchi, Y Shimomura.   

Abstract

Articular chondrocytes cultured in the presence of recombinant human interleukin 1 alpha (rhIL-1 alpha) or recombinant human tumor necrosis factor alpha (rhTNF alpha) caused increased production of the latent metalloproteinase (collagenase and caseinase) and the proteoglycan release from cartilage. The existences of IL-1 and TNF alpha in the chondrocytes of human articular cartilage were also shown by immunohistochemical staining using polyclonal antibodies. Furthermore, chondrocyte was found to be a producer of interleukin 6 (IL-6), known as a pleiotropic cytokine and thought to be an important mediator of the cell interactions in arthritis. In addition, the production of IL-6 was also shown to be stimulated by rhIL-1 alpha or rhTNF alpha. From our findings, we suggest there exists a very complicated autocrine control system of chondrolysis by the chondrocyte itself.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810294

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  11 in total

1.  Cellular responses to human chondrocytes: absence of allogeneic responses in the presence of HLA-DR and ICAM-1.

Authors:  P Jobanputra; V Corrigall; G Kingsley; G Panayi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

3.  New cell lines with chondrocytic phenotypes from human chondrosarcoma.

Authors:  Ikuo Kudawara; Nobuhito Araki; Akira Myoui; Yoichi Kato; Atsumasa Uchida; Hideki Yoshikawa
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

4.  Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats.

Authors:  R Di Paola; E Mazzon; C Muià; C Crisafulli; D Terrana; S Greco; D Britti; D Santori; G Oteri; G Cordasco; S Cuzzocrea
Journal:  Br J Pharmacol       Date:  2007-01-02       Impact factor: 8.739

Review 5.  Cytokines and proteoglycans.

Authors:  J J Nietfeld
Journal:  Experientia       Date:  1993-05-15

Review 6.  Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.

Authors:  P J Mease
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

7.  Dexamethasone Release from Within Engineered Cartilage as a Chondroprotective Strategy Against Interleukin-1α.

Authors:  Brendan L Roach; Arta Kelmendi-Doko; Elaine C Balutis; Kacey G Marra; Gerard A Ateshian; Clark T Hung
Journal:  Tissue Eng Part A       Date:  2016-03-31       Impact factor: 3.845

8.  Modulation of proteases and their inhibitors in immortal human osteoblast-like cells by tumor necrosis factor-alpha in vitro.

Authors:  F S Panagakos; S Kumar
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

9.  Effects of interleukin-1 on syntheses of alkaline phosphatase, type X collagen, and 1,25-dihydroxyvitamin D3 receptor, and matrix calcification in rabbit chondrocyte cultures.

Authors:  Y Kato; K Nakashima; M Iwamoto; H Murakami; H Hiranuma; T Koike; F Suzuki; H Fuchihata; Y Ikehara; M Noshiro
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 10.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.